Precision for Medicine

The move will gain PFM a Houston lab, as well as ApoCell's proprietary ApoStream liquid biopsy technology for isolation and capture of circulating tumor cells.

The deal provides Precision for Medicine with a proprietary PCR-based technology that amplifies and detects euchromatic DNA expressed exclusively by cell types of interest.

The deal joins Precision for Medicine's suite of biomedical research tools and services with ACT Oncology's expertise in clinical study design and execution.

PATH is designed to help users combine and use clinical and genomic information to stratify patients as part of efforts to develop more tailored therapies.

CEOs at four of the five leading mass spec firms saw their total compensation dip last year, according to information provided in their proxy statements, with Bill Sullivan at Agilent taking the biggest hit, a 39 percent drop from his 2007 earnings. Meanwhile, Frank Laukien at Bruker received an 80 percent upgrade in 2008.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.